Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Incidence of Bacteremia Following Argon Plasma Coagulation in Patients with Endobronchial Lesions

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques

NCT00449306

Atherosclerosis Aortic Aneurysm Peripheral Vascular Diseases

UNKNOWN

The Association of Platelet Function and Endothelial Function of the Brachial Artery

NCT00363818

Coronary Artery Disease Endothelial Function Thrombosis

COMPLETED

Platelet Leukocyte Aggregates in Acute Cardiac Syndrome vs Healthy Volunteers

NCT01797016

Myocardial Infarction

COMPLETED

Chlamydia and Mycoplasma in Coronary Artery Disease

NCT00561028

Atherosclerosis Coronary Artery Disease Chlamydia Infections +1 more

COMPLETED

Transient ECG Changes in Patients With Acute Biliary Disease

NCT01706068

Acute Cholecystitis Biliary Colic Acute Cholangitis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bacteremia is a well-recognized invasive medical condition. In most cases, it is a transient phenomenon without clinical consequences. In certain patients, such as those with structural cardiac abnormalities, it may lead to the development of infectious endocarditis. According to an American Heart Association statement, routine endocarditis prophylaxis is indicated prior to invasive procedures with relatively high bacteremia rates, such as dental care,certain types of catheterization and rigid bronchoscopy \[1\].Fibreoptic bronchoscopy, with or without biopsy is not included in this list due to a very low bacteremia rate \[1\].This even applies to particularly high risk patients with prosthetic valve or previous endocarditis. Yigla et al. assessed the incidence of bacteremia following bronchoscopy and found 6.5% of bacteremia rate. (2) Recently, Steinfort et al. assessed the bacteremia rate following endobronchial ultrasound and found 7% of bacteremia rate following the procedure. All bacterial isolates were typical oropharyngeal commensal organisms. The transbronchial needle aspiration washing culture was positive in 35% of the patients. However, none of the bacteremic patients had clinical features suggestive of infection and no complications were seen among the cohort. (3) No data are available, however about the bacteremic rate following interventional bronchoscopy for endobronchial obstruction and advance lung carcinoma. In these cases, palliative setting of alleviating central airway obstruction, laser resection, electrocautery, argon plasma coagulation and stenting are techniques that can provide immediate relief.

Argon plasma coagulation (APC) is uses ionize argon gas jet flow to conduct electrons allowing a noncontact mode of treatment (lightning effect). (4, 5) APC has been popular in gastrointestinal endoscopy for superficial coagulation of large mucosal surfaces. The argon gas quite flexibly flows around bends and corners. Coagulated tissue has a higher resistance that automatically drives the argon gas flow away to nearby untreated tissue. An immediate effect really can be seen during electrocautery treatment, which corresponds well with the histological effect of coagulative necrosis.

We therefore conduct a prospective study to assess the bacteremic rate following APC in patients with endobronchial involvement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacteremia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients that undergo bronchoscopy with the use of APC

Exclusion Criteria

* All patients under 18 years old All Patients with evidence of current respiratory infection or febrile illnesses and those that will receive antibiotic therapy within a week prior to the bronchoscopy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No